Last reviewed · How we verify
Course of amoxicillin
Course of amoxicillin is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved.
Amoxicillin, marketed by Assistance Publique - Hôpitaux de Paris, is a well-established antibiotic with a key composition patent expiring in 2028. The drug's primary strength lies in its broad-spectrum efficacy and widespread acceptance in treating bacterial infections. The primary risk is the potential increase in generic competition following the 2028 patent expiry.
At a glance
| Generic name | Course of amoxicillin |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children (PHASE2)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer (PHASE2)
- Early Antibiotics After Aspiration in ICU Patients (PHASE4)
- Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases (PHASE4)
- Evaluation of the Use of a Probiotic Containing Bifidobacterium Breve PRL2020 in Oral Drops in Preventing Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid Antibiotic Use (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Course of amoxicillin CI brief — competitive landscape report
- Course of amoxicillin updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI